Item Details
Chinese Biotech Firm Metis TechBio Signs Drug-Development Deal Worth Up to US$1.1 Billion
On 21 October, City News Service reported that China’s Metis TechBio had entered into an agreement with Eli Lilly valued at up to US$1.1 billion to research and develop tissue-specific drug-delivery technologies. The maximum headline value is contingent on the agreement’s terms and is not necessarily an upfront payment; pharmaceutical companies, research institutions and healthcare technology providers can explore clinical-data analysis and research-computing requirements, while HPC can provide suitable data-processing support with quotations based on confirmed project needs.
Get in Touch
We’ll get back to you shortly.